Vnitr Lek 2006, 52(11):1069-1076

Affection of cardiovascular system in diabetic patients with thyroid dysfunctions

Z. Schroner1,*, I. Lazúrová2
1 NZZ interná a diabetologická ambulancia, Moldava nad Bodvou, Slovenská republika
2 I. interná klinika Lekárskej fakulty UPJŠ a FN L. Pasteura, Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc.

Affection of cardiovascular system is one of the most frequent and - especially in higher age groups - the most serious clinical manifestations of thyroid dysfunction. Moreover, diabetics, mainly type 2 diabetes patients, have a marked predisposition to cardiovascular diseases, especially to atherosclerosis and its visceral complications. Simultaneous occurrence of diabetes mellitus (DM) and thyroid dysfunctions involves a very high risk of development and progression of various forms of cardiovascular diseases. There are two basal aspects of the influence of hypothyreosis on cardiovascular system. Decreasing basal metabolism in the whole organism reduces requirements on the cardiovsuclar system. The second aspect of the influence of hypothyreosis on the cardiovascular system is its atherogenic effect. Hypothyreosis in diabetics accelerates the development of chronic, primarily macroangiopathic complications. As opposed to hypothyreosis, the clinical picture of which is not characterised by cardiovascular system disorders, cardiac involvement in patients with hyperthyreosis is more pronounced. In older diabetics hyperthyreosis is often manifested only by cardiovascular symptomatology. Subclinical hyperthyreosis in DM patients may stimulate cardiac function and increase the risk of atrial fibrillation.

Keywords: cardiovascular system; diabetes mellitus; hypothyreosis; hyperthyreosis

Received: May 12, 2006; Accepted: July 20, 2006; Published: November 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Schroner Z, Lazúrová I. Affection of cardiovascular system in diabetic patients with thyroid dysfunctions. Vnitr Lek. 2006;52(11):1069-1076.
Download citation

References

  1. Zamrazil V, Váňa S, Němec J. Štítná žláza a kardiovaskulárny systém. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 468-477.
  2. Belicová M, Smatanová S, Lilgová M et al. Diabetes mellitus a srdce. Diabetes a obezita 2003; 3: 8-16.
  3. Klein I, Ojama K Cardiovascular manifestations of endocrine diseases. J Clin Endocrin Metab 1992; 75: 339-342. Go to original source...
  4. Běhanová M, Nedvídková J. Periférní účinky tyreoidálních hormonu. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 283-295. Go to original source...
  5. Payer J. Kardiálne prejavy hypertyreózy. Kardiológia 1997; 6: 71-74.
  6. Polikar R, Burger AG, Scherrer U et al. The thyroid and the heart. Circulation 1993; 87: 1435-1441. Go to original source... Go to PubMed...
  7. Klein J, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotypically transplanted rat heart. J Clin Invest 1986; 77: 1694-1698. Go to original source... Go to PubMed...
  8. Kahaly G, Beyer J. Kardiale beteiligung bei Functionsstorungen der Schilddruse. Dtsch Med Wschr 1991; 116: 1559-1562. Go to original source... Go to PubMed...
  9. Klein I, Levy GS. New perspectives on thyroid hormone, catecholamines and heart. Am J Med 1984; 76: 167-172. Go to original source... Go to PubMed...
  10. Forfar J, Caldwell G. Hyperthyroid heart disease. J Clin Endocrin Metab 1985; 14: 491-508. Go to original source... Go to PubMed...
  11. De Groot WJ, Leonard J. Hyperthyreoidism as a high cardiac output state. Am Heart J 1970; 79: 265-275. Go to original source... Go to PubMed...
  12. Král J, Hradec J et al. Heart in thyroid diseases. Cor Vasa 1992; 34: 108-114.
  13. Woeber KA Thyrotoxicosis and the heart. N Engl J Med 1992; 327: 94-98. Go to original source... Go to PubMed...
  14. Vondra K, Zamrazil V. Onemocnění štítné žlázy u nemocných s diabetes mellitus. DMEV 2002; 5: 78-84.
  15. Schroner Z, Pella J. Diabetes mellitus v skratke. Košice: Oriens 2002.
  16. Rašlová K, Flipová G, Mikeš Z et al. Odporúčania pre optimálnu diagnostiku a liečbu dyslipoproteinémií u dospelých. Lipidový konsenzus - 2. Interná med 2002; 3: 10-18.
  17. Tkáč I Možnosti prevencie aterosklerózy pri diabetes mellitus 2. typu. Interná Med 2003; 3: 149-153.
  18. Krahulec B. Inzulínová rezistencia a kardiovaskulárne následky - významaná úloha endotelovej dysfunkcie. Diabetes a obezita 2003; 3: 9-15.
  19. Hak AE, Pols HAP et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Int Med 2000; 132: 270-278. Go to original source... Go to PubMed...
  20. Bakker SJL, Maaten JC, Popp-Snijders C et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001; 86: 1206-1211. Go to original source...
  21. Lien EA, Nedrebo BG, Varhaug JE et al. Plasma total homocystein levels during short term iatrogenic hypothyroidism. J Clin Endocrinol Metab 2000; 85: 1049-1053. Go to original source...
  22. Pella D, Rybár R et al. Ateroskleróza a artériová hypertenzia. Interná med 2001; 1: 86-90.
  23. Češka R. Cholesterol a ateroskleróza. Praha: Maxdorf, 1990.
  24. Vrablík M, Češka R. Sekundární dyslipoproteinémie. Via Practica 2004; 1: 14-17.
  25. Fabryová Ľ. Manažment kardiovaskulárneho rizika u pacientov s metabolickým syndrómom. Interná Med 2004; 4: 35-42.
  26. Fabryová Ľ. Dyslipoproteinémie. In: Kreze A, Langer P, Klimeš I et al. Všeobecná a klinická endokrinológia. Bratislava: Academic Electronic Press 2004: 553-567.
  27. Límanová Z. Choroby štítné žlázy. In: Klener P et al. Vnitřní lékařství. Praha: Galén 2001: 763-777.
  28. Kiňová S. Endokrinné formy hypertenzie. Interná Med 2004; 4: 286-290.
  29. Vavrejnová V, Nedvídková J et al. Zvýšení hladiny noradrenalinu při hypotyreoze a jeho souvislosti s činností kardiovaskulárního systému. Vnitř Lék 1992; 38: 1195-1200. Go to PubMed...
  30. Phull PS, Collins CE et al. Variant angina in thyrotoxicosis. Br J Clin P 1993; 47: 17-19. Go to original source...
  31. Němec J, Stárka L Preklinické poruchy tyreoidální funkce. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 392-399.
  32. Límanová Z, Němec J, Zamrazil V. Nemoci štítné žlázy. Praha: Galén 1997.
  33. Presti CHF, Hart R Thyrotoxicosis, atrial fibrillation and embolism revisited. Am Heart J 1989; 4: 975-976. Go to original source... Go to PubMed...
  34. Nakazawa HK, Sakuri K et al. Management of atrial fibrillation in the post thyrotoxic state. Am J Med 1982; 72: 903-906. Go to original source... Go to PubMed...
  35. Zamrazil V, Němec J. Vliv amiodaronu na štítnou žlázu. In: Stárka L et al. Aktuální endokrinologie. Praha: Maxdorf 1999: 415-424.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.